-
Post date
July 4, 2021
-
Posted by
Lukas Kane
-
Posted in
Biotech, Breakthrough Therapy, Bucillamine, CBD research and development, clinical testing, Fast Track, FDA approval, Featured Content, Health Science, ischemia-reperfusion injury, Kane, Mushroom Moves, Mushrooms, Orphan Drug, preclinical testing, preclinical trials, psilcoybin, Psychedelics, Rare Pediatric Disease, research and development, Revive Therapeutics, RVV.C, Scribes, Series, UCSF, University of California